BRIEF-Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 – Reuters

April 4 Puma Biotechnology Inc:

* Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 in extended adjuvant treatment of HER2-positive early stage breast cancer at the 2017 AACR annual meeting

* Results of Phase II CONTROL trial showed incidence of grade 3 diarrhea for 137 patients who received loperamide prophylaxis was 30.7%

* For 137 patients who received loperamide prophylaxis in Phase II CONTROL trial, 20.4% discontinued neratinib due to diarrhea

* Reductions seen in incidence of severe neratinib-related diarrhea in CONTROL trial Source text for Eikon: Further company coverage:

The following factors could affect Italian markets on Wednesday.

* Gogo secures capacity on 12 transponders across two SES satellites Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

April 5 Britain's FTSE 100 index is seen opening 5 points higher on Wednesday, according to financial bookmakers, with futures up 0.3 percent ahead of the cash market open.

The rest is here:
BRIEF-Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 - Reuters